Cramer's lightning round: Onto Innovation is 'going to go lower' - CNBC
UiPath: "It's a cheap, cheap stock, but it has no catalyst, so I have to vote it off the island."
Karman Holdings: "It's so darn cheap. I can't go against it here. I have to tell you, I think you got something right here. ... I'm going to actually bless it."
Affirm: "We're fighting the Fed if we buy the stock. If you want to start up a new position, I bless it right here. ... If you want to buy 100 shares, at $56, you buy 25, then at $50, you buy 25, and then heaven's if it gets to $45, you should buy 50. That's because I'm not backing away from [CEO] Max Levchin. His numbers are too good."
Onto Innovation: "Good company, but it's going to go lower because it's too expensive in an environment where the Fed is fighting inflation."
Nio: "I got to tell you, $2 stocks, you know where they can go? They stop at zero, and that's always been the saving grace of a $2 stock. I suggest that you, as long as you don't mind losing the two bucks, you can hold on for it."
Alnylam Pharmaceuticals: "This is an inexpensive stock. I happen to like his partner Regeneron more, though. Just for the record, Regeneron, Vertex, and Amgen all work better."
Questions for Cramer? Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer's world? Hit him up! Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram
Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com